Anti-GAB1 antibody

• WB

Unknown

Western blot - Anti-GAB1 antibody (AB59362)

All lanes:

Western blot - Anti-GAB1 antibody (ab59362) at 1/500 dilution

Lane 1:

Extracts from NIH/3T3 cells with no immunizing peptide

Lane 2:

Extracts from NIH/3T3 cells with immunizing peptide

Predicted band size: 77 kDa

Observed band size: 77 kDa

false

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-GAB1 antibody (AB59362)

ICC/IF image of ab59362 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab59362, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GAB1 antibody (AB59362)

ab59362, at a 1/50 dilution, staining human GAB1 in breast carcinoma, using Immunohistochemistry, Paraffin embedded tissue, in the absence of the immunizing peptide (left image) and in the presence of the immunizing peptide (right image).

• WB

CiteAb

Western blot - Anti-GAB1 antibody (AB59362)

GAB1 western blot using anti-GAB1 antibody ab59362. Publication image and figure legend from Hu, Y., Xie, L., et al., 2019, Mol Med, PubMed 31892308.

ab59362 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab59362 please see the product overview.

GAB1 is a target gene of miR-29a. A, Predicted binding site between miR-29a and GAB1. B, The binding of miR-29a to GAB1 verified by dual-luciferase reporter gene assay. *p < 0.05 vs. the cells co-transfected with mimic-NC and pMIR-GAB1-Wt plasmids or pMIR-GAB1-Mut plasmids (the mimic-NC group). C&D, Western blot analysis of GAB1 protein in MLE-12 cells of each group. *p < 0.05 vs. MLE-12 cells transfected with mimic-NC (the mimic-NC group). #p < 0.05 vs. MLE-12 cells delivered with inhibitor-NC (the inhibitor-NC group). E&F, the positive expression of GAB1 protein in lung tissues of each group detected by immunohistochemistry (× 400). *p < 0.05 vs. neonatal mice under exposure of RA (the RA group). #p < 0.05 vs. neonatal mice with hyperoxia-induced BPD receiving miR-29a antagomir administration (the BPD + miR-29a antagomir group). N = 15. Measurement data were expressed as mean ± standard error. Data comparison between two groups was examined by unpaired t-test. The experiment was repeated 3 times independently. miR-29a, microRNA-29a; GAB1, GRB2-associated-binding protein 1; BPD, bronchopulmonary dysplasia; RA, room air; Wt, wild type; Mut, mutant; NC, negative control

false